Related Experiment Video

Updated: Jan 12, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.4K

G Protein-Coupled Receptor 35 Holds Potential as a Beacon of Hope for Treating Chondrosarcoma

A Tuncal1, R Kalkan2

  • 1Department of Medical Biochemistry, Faculty of Medicine, Cyprus Health and Social Sciences University, Morphou, Northern Cyprus.

Balkan Journal of Medical Genetics : BJMG
|November 7, 2025
PubMed
Abstract

Insights

Bisacodyl shows potential as a therapeutic agent for chondrosarcoma, a rare bone cancer. This study identified bisacodyl as a targeted treatment for chondrosarcoma cell lines, offering new hope for patients.

Area of Science:

  • Oncology
  • Cartilage Biology
  • Cancer Genetics

Background:

  • Chondrosarcomas are primary bone cancers characterized by neoplastic hyaline cartilage.
  • Traditional chondrosarcomas exhibit resistance to conventional treatments, leading to poor prognoses upon recurrence.
  • Recent advancements in understanding chondrosarcoma biology, genetics, and epigenetics are revealing potential therapeutic targets.

Purpose of the Study:

  • To identify potential targeted treatments for chondrosarcoma.
  • To evaluate bisacodyl as a therapeutic agent against chondrosarcoma cell lines.
  • To explore the role of G protein-coupled receptors in chondrosarcoma treatment.

Main Methods:

  • In silico screening using Gene2 drug and DSEA.
  • Extraction of antitumor activities from the DepMap database.
  • Antitumor activity assessment via PRISM viability assays on eight chondrosarcoma cell lines.

Main Results:

  • Bisacodyl was identified as a targeted agent against G protein-coupled receptor 35.
  • Bisacodyl demonstrated significant antitumor activity in chondrosarcoma cell lines.
  • G protein-coupled receptors are recognized as viable targets for cancer therapy.

Conclusions:

  • Bisacodyl represents a promising therapeutic candidate for chondrosarcoma.
  • Targeted therapies focusing on G protein-coupled receptors offer a new avenue for chondrosarcoma treatment.
  • Further research into bisacodyl's efficacy and mechanism in chondrosarcoma is warranted.
Keywords:
CDS1CHEK2bisacodylchondrosarcomatargeted treatment

More Related Videos

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 406:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

14.4K

Related Concept Videos

G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.4K
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
131.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
3.9K